Juniper Biologics, a science-led healthcare company, announced that it has gained the licensing rights to develop and commercialize TG-C LD (TissueGene-C low dose) for the treatment of knee osteoarthritis.
The $600 million USD licensing deal which covers Asia Pacific, Middle East and Africa was signed with Kolon Life Science, and is Juniper Biologics
